Imaging biomarker roadmap for cancer studies

@inproceedings{OConnor2017ImagingBR,
  title={Imaging biomarker roadmap for cancer studies},
  author={James P. B. O’Connor and Eric Ofori Aboagye and Judith Adams and Hugo J. W. L. Aerts and Sally F Barrington and Ambros J. Beer and Ronald Boellaard and Sarah Elizabeth Bohndiek and Michael Brady and G. S. Brown and David L. Buckley and Thomas L. Chenevert and Laurence P. Clarke and Sandra Collette and Gary J. R. Cook and Nandita M deSouza and John C. Dickson and Caroline Dive and Jeffrey L. Evelhoch and Corinne Faivre-Finn and Ferdia A Gallagher and Fiona J. Gilbert and Robert J. Gillies and Vicky Goh and John R. Griffiths and Ashley M. Groves and Steve Halligan and Adrian L. Harris and David J. Hawkes and Otto S. Hoekstra and Erich P. Huang and Brian F. Hutton and Edward Jackson and Gordon C. Jayson and Andrew L. Jones and Dow-Mu Koh and Denis A Lacombe and Philippe Lambin and Nathalie Lassau and Martin O. Leach and Ting-Yim Lee and Edward Leen and Jason S Lewis and Yan Liu and Mark F. Lythgoe and Prakash Manoharan and Ross James Maxwell and Kenneth Miles and Barbier Morgan and Steve Morris and Tony Ng and Anwar R. Padhani and Geoffrey J. M. Parker and Mike Partridge and Arvind P. Pathak and Andrew C Peet and Shonit Punwani and Andrew R. Reynolds and Simon P Robinson and Lalitha K. Shankar and Ricky A. Sharma and Dmitry A Soloviev and Sigrid Stroobants and Daniel Carl Sullivan and Stuart A. Taylor and Paul S. Tofts and Gillian M. Tozer and Marcel B van Herk and Simon Walker-Samuel and James M. S. Wason and Kaye J. Williams and Paul Workman and Thomas E. Yankeelov and Kevin M Brindle and Lisa M. McShane and Alan Jackson and John C. Waterton},
  booktitle={Nature Reviews Clinical Oncology},
  year={2017}
}
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 95 times over the past 90 days. VIEW TWEETS